NasdaqGS:COLLPharmaceuticals
Collegium Pharmaceutical Expands ADHD Portfolio With AZSTARYS And Valuation Gap
Collegium Pharmaceutical (NasdaqGS:COLL) has entered into a definitive agreement to acquire AZSTARYS.
The deal expands Collegium’s ADHD portfolio and secures longer-term product exclusivity for its ADHD offerings.
The transaction is described as immediately accretive to adjusted EBITDA.
For investors following the ADHD treatment space, this move provides another data point on how branded therapies are being repositioned. Collegium, which focuses on pain and ADHD treatments, is adding...